CMS finalizes Medicare drug price negotiation rule covering up to 20 drugs a year
CMS made Medicare drug price negotiation permanent by rule, with up to 20 drugs a year starting in 2029.
Objective Facts
The Centers for Medicare & Medicaid Services issued a final rule on Nov. 5, 2026, that writes the Medicare Drug Price Negotiation Program into federal regulation starting with prices effective in 2029. Negotiation for 2026 through 2028 ran on agency guidance, and the new rule takes effect Dec. 5, 2026, according to the CMS fact sheet. By Feb. 1, 2027, CMS will select up to 20 more drugs covered under Part D or Part B for the fourth cycle, and it may also pick previously negotiated drugs for renegotiation. Pharmaceutical Commerce reported that CMS received about 11,330 comment letters and finalized, over objections from drugmakers and more than 50 lawmakers, a policy that treats certain new combination formulations as part of the older drug. CMS gave no dollar savings estimate for the rule, Jolt Journal noted.
Left-Leaning Perspective
Mainstream left coverage of the final rule was thin in what this search could read. STAT's John Wilkerson reported in June that the proposal aimed to close a loophole drugmakers use to avoid negotiation, but the full story is paywalled. The Center for American Progress, a left-leaning think tank, argued in November 2025 that negotiation is working and that CMS should close loopholes and lift caps on how many drugs it negotiates. That position supports the combination drug policy CMS just finalized, though the CAP piece predates the rule.
Right-Leaning Perspective
Right-leaning coverage centered on the combination drug policy before it was finalized. Fox News Digital's Sophia Compton reported in September that more than 50 lawmakers from both parties, led in part by Republican Reps. John Joyce and Darin LaHood, asked Oz to drop it, saying it would hurt cancer patients who benefit from quick injections instead of long IV infusions. Former Congressional Budget Office director Dan Crippen, writing in CT Examiner in October, argued that the IRA's price controls are already cutting research and cited the same proposed policy as a further risk. CMS finalized the policy anyway.
Deep Dive
The 2022 Inflation Reduction Act told CMS to run the first three negotiation cycles through guidance, and Pharmaceutical Commerce reported that this requirement ends after 2028. The Nov. 5 rule fills that gap. It applies to the fourth cycle, when CMS will name up to 20 drugs by Feb. 1, 2027, for prices starting in 2029, and it also governs drugs picked in earlier rounds from 2029 on. Prior cycles covered 10 drugs for 2026, 15 for 2027 and 15 for 2028. CMS waived the usual 60-day delay for major rules so the rule takes effect Dec. 5. CMS's case is that the rule gives drugmakers predictability while closing a path to avoid negotiated prices. The most contested piece, the fixed combination drug policy, targets products like IV biologics reformulated with hyaluronidase for injection. Pharmaceutical Commerce reported that commenters said the policy discounts development costs and falls hardest on small biotechs, and the lawmakers' letter said CMS actuaries had not shown meaningful savings. CMS did not release a savings figure, which leaves that claim untested in public. Halozyme, the main supplier of hyaluronidase technology, told investors it expects zero to minimal royalty impact through at least 2035, which suggests the near-term commercial effect may be smaller than the political fight implies. Hospitals have their own concern: the American Hospital Association asked CMS to require point-of-sale pricing rather than retrospective rebates, and the rule leaves payment mechanics to later guidance. The next markers are fall 2026 guidance on putting 2028 negotiated prices into effect, including for Part B drugs, and a 2027 rulemaking on how those prices are paid for 2029 and later. The Feb. 1, 2027, drug list will show how far the combination drug policy reaches. Legal challenges are possible, since PhRMA sued CMS in October over a separate Part B pricing model, according to a related item on the Global Relay Intelligence & Practice site, though no suit against this rule had been reported.